MRNA - Conference and earnings call announcements

CAMBRIDGE, MA / ACCESSWIRE / November 25, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced its participation in the following upcoming investor conferences:7th Annual Evercore ISI HealthCONx Conference, on Wednesday, December 4th at 1:20pm ETPiper Sandler 36th Annual Healthcare Conference, on Thursday, December 5th at 10:30am ETA live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation.About ModernaModerna is a leader in the creation of the field of mRNA medicine. Thr

CAMBRIDGE, MA / ACCESSWIRE / October 31, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced its participation in the following upcoming investor conferences:Guggenheim's Inaugural Healthcare Innovation Conference, on Tuesday, November 12th at 10:00am ETUBS Global Healthcare Conference, on Wednesday, November 13th at 3:30pm PTJefferies London Healthcare Conference, on Thursday, November 21st at 2:00pm GTA live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation.About Mod

CAMBRIDGE, MA / ACCESSWIRE / August 22, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host its Investor Event - R&D Day and Business Updates at 9:00 a.m. ET on Thursday, September 12, 2024.The event will include presentations from management discussing Moderna's development and commercial strategy and key business considerations. A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna's website for at least 30 days following the presentation.About ModernaModerna is a leader in the creation of the field of mRNA medicine

Center for Biologics Evaluation and Research has chosen mRNA-3705 as one of four investigational medicines for accelerated development to address unmet medical needs for rare diseases CAMBRIDGE, MA / ACCESSWIRE / June 6, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has selected mRNA-3705 for the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program. mRNA-3705 is an investigational therapeutic for methylmalonic acidemia (MMA) due to methylmalonic-CoA mutase (MUT) deficiency."We are excited about this opportunity and proud that our investigational mRNA therapeutic for MMA was selected by the U.S. FDA for the

Moderna to host an investor event via webcast on Monday, June 3 at 6:15 PM CDTCAMBRIDGE, MA / ACCESSWIRE / May 22, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on mRNA-4157 (V940), an investigational mRNA individualized neoantigen therapy, have been accepted for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31 - June 4 in Chicago, IL. mRNA-4157 (V940) is being jointly developed by Moderna and Merck, known as MSD outside of the United States and Canada.The three abstract titles are:Abstract #TPS9616: INTerpath-001: Pembrolizumab with V940 (mRNA-4157) versus pembrolizumab with placebo for adjuvant treatme

CAMBRIDGE, MA / ACCESSWIRE / May 13, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced its participation in the following upcoming investor conferences:Bernstein's 40th Annual Strategic Decisions Conference (SDC), on Friday, May 31st at 10:00am ETJefferies Healthcare Conference, on Thursday, June 6th at 10:00am ETGoldman Sachs 45th Annual Global Healthcare Conference, on Monday, June 10th at 1:20pm ETA live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation.About Mode

CAMBRIDGE, MA / ACCESSWIRE / February 29, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host its fifth annual Investor Event focused on vaccines and business updates on Wednesday, March 27, 2024. The presentation will begin at 9:00 a.m. ET.Moderna's Investor Event will include presentations from management on Moderna's pipeline of mRNA vaccines. A live webcast will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna's website for one year following the presentation.About ModernaModerna is a leader in the creation of the field of mRNA medicine. Through th

CAMBRIDGE, MA / ACCESSWIRE / February 28, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced its participation in the following upcoming investor conferences:TD Cowen 44th Annual Healthcare Conference, on Wednesday March 6th at 1:30 pm ET.Barclays 26th Annual Global Healthcare Conference, on Tuesday March 12th at 2:35 pm ET.A live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation.About ModernaModerna is a leader in the creation of the field of mRNA medicine. Through t

CAMBRIDGE, MA / ACCESSWIRE / December 20, 2023 / Moderna, Inc. (NASDAQ:MRNA), today announced that Jamey Mock, Chief Financial Officer, will present at the 42nd annual J.P. Morgan Healthcare Conference on Monday, January 8th at 6:45 p.m. ET / 3:45 p.m. PT.A live webcast of each presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation.About ModernaModerna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made

The Company's ESG strategy demonstrates its efforts to advance global health and environmental sustainability, as well as its commitments to employees and communitiesCAMBRIDGE, MA / ACCESSWIRE / December 7, 2023 / Moderna, Inc. (NASDAQ:MRNA) today will provide an update on its Environmental, Social and Governance (ESG) strategy at its second ESG Investor Event. Building off its inaugural ESG Day in November 2022, the Company will highlight the year's progress on its ESG journey and future work to further impact global health and protect the environment."Our mRNA platform science has benefited patients around the world and with that comes great responsibility as science alone will not solve t

CAMBRIDGE, MA / ACCESSWIRE / November 14, 2023 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host its second virtual ESG investor event at 8:00 a.m. ET on Thursday, December 7, 2023.Moderna's ESG Investor Event will include presentations from management on Moderna's ESG strategy.A live webcast of the event will be available under "Events and Presentations" in the Investors section of the Moderna website.Webcast: https://investors.modernatx.comThe archived webcast will be available on Moderna's website and will be available for one year following the call.About ModernaIn over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs i

CAMBRIDGE, MA / ACCESSWIRE / November 8, 2023 / Moderna, Inc. (NASDAQ:MRNA), today announced its participation in the following upcoming investor conferences:2023 UBS Global Biopharma Conference on November 9th at 8:00 a.m. ET.2023 Jefferies London Healthcare Conference on November 16th at 8:30 a.m. GMT.35th Annual Piper Sandler Healthcare Conference on November 30th at 12:30 p.m. ET.A live webcast of each presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation.About ModernaIn over 10 years since its

The Company demonstrates how its integrated Artificial Intelligence ecosystem accelerates innovation at scale and creates value across the enterpriseModerna to present case studies on how the organization is building a real-time AI CompanyCAMBRIDGE, MA / ACCESSWIRE / November 8, 2023 / Moderna, Inc. (NASDAQ:MRNA) today will unveil its comprehensive AI and digital strategy at its second Digital Investor Event. Building off its Manufacturing and Digital Day hosted in March 2020, the Company will showcase how AI continues to transform the organization and enhance its value creation. Today's presentation will highlight Moderna's leading position in AI-powered innovation, its ability to harness t

CAMBRIDGE, MA / ACCESSWIRE / October 19, 2023 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a virtual Digital and AI Investor Event at 8:00 a.m. ET on Wednesday, November 8, 2023.The event will include presentations from management discussing Moderna's digital strategy and the role of AI in accelerating its innovation, scale and value creation. The company will discuss a range of AI applications across the value chain, from drug design through commercialization, demonstrating the transformative power of AI. This event builds on the Manufacturing and Digital Day hosted by the company on March 4, 2020.A webcast of the event will be available under "Events and Presentations"

Company's flu vaccine, mRNA-1010, met its primary endpoint in Phase 3 trial; separate Phase 1/2 data demonstrated higher HAI titers than Fluzone HDVaccine pipeline advancing rapidly with Company announcing the completion of RSV BLA filing (mRNA-1345), completion of adult enrollment in the Phase 3 trial of mRNA-1647, a first-in-class vaccine against CMV, and the Phase 3 trial of mRNA-1283, a next-generation COVID-19 vaccineWith its partner Merck, the Company plans to begin a second Phase 3 trial of mRNA-4157, its individualized neoantigen therapy (INT), in combination with Keytruda®, for non-small cell lung cancer later this year; updated efficacy follow-up from the ongoing Phase 2 study in a

CAMBRIDGE, MA / ACCESSWIRE / August 30, 2023 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host its Investor Event - R&D Day and Business Updates at 1:00 p.m. ET on Wednesday, September 13, 2023.The event will include presentations from management discussing Moderna's development and commercial strategy and key business considerations. A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna's website for at least 30 days following the presentation.About ModernaIn over 10 years since its inception, Moderna has transformed fr

Study participants include children up to and including 36 months who attend group child care and early childhood education settings located in Worcester and Cambridge WORCESTER, Mass., Aug. 14, 2023 /PRNewswire/ -- UMass Chan Medical School today announced it will begin enrolling participants at group child care and early childhood education settings in Worcester and Cambridge to examine the impact of cytomegalovirus (CMV) transmission. The study is a collaboration with Moderna (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA)-based therapeutics and vaccines, which is currently researching a vaccine for CMV.

CAMBRIDGE, MA / ACCESSWIRE / June 1, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the following upcoming investor conferences:2023 Jefferies Healthcare Conference on Thursday, June 8th at 10:30 a.m. ET44th Annual Goldman Sachs Global Healthcare Conference on Wednesday, June 14th at 4:40 p.m. PSTA live webcast of each presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna's website for at least 30 days following the presentation.About ModernaIn over

ASCO presentations on Saturday, June 3 at 4:30pm CDT and Monday, June 5 at 3:00pm CDTModerna to host investor event via webcast on Monday, June 5 at 6pm CDTCAMBRIDGE, MA / ACCESSWIRE / May 30, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that two abstracts on mRNA-4157 (V940), an investigational mRNA individualized neoantigen therapy, have been accepted for presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 2-6 in Chicago, IL. mRNA-4157 (V940) is being jointly developed by Moderna and Merck, known as MSD outside of the United States and Canada.The two ab

CAMBRIDGE, MA / ACCESSWIRE / February 28, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in a fireside chat at Cowen's 43rd Annual Health Care Conference on Monday, March 6th at 9:10 a.m. ET.A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna's website for at least 30 days following the presentation.About ModernaIn over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the

Collaboration will combine Moderna's mRNA technology with CytomX's Probody® Platform to generate and develop therapeutics for oncology and non-oncology conditionsCytomX to receive $35 million upfront payment with the potential for additional research, milestone, and royalty paymentsCAMBRIDGE, MA and SOUTH SAN FRANCISCO, CA / ACCESSWIRE / January 5, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced a collaboration and licensing agreement to create investigational mRNA-based conditionally activa

Collaboration will combine Moderna's mRNA technology with CytomX's Probody® Platform to generate and develop therapeutics for oncology and non-oncology conditions CytomX to receive $35 million upfront payment with the potential for additional research, milestone, and royalty payments SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated oncology therapeutics and Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a collaboration and licensing agreement to create investigational mRNA-based co

CAMBRIDGE, MA / ACCESSWIRE / November 29, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Thursday, Dec. 1st at 9:00 a.m. ET.A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna's website for at least 30 days following the presentation.About ModernaIn 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in

CAMBRIDGE, MA / ACCESSWIRE / November 9, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in a fireside chat at the Jefferies 2022 London Healthcare Conference on Wednesday, Nov. 16th at 8:30 a.m. ET.A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna's website for at least 30 days following the presentation.About ModernaIn 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in th

CAMBRIDGE, MA / ACCESSWIRE / September 6, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Stephen Hoge, M.D., President, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13th at 10:00 a.m. ET.A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna's website for at least 30 days following the presentation.About ModernaIn 10 years since its inception, Moderna has transformed fr

CAMBRIDGE, MA / ACCESSWIRE / June 1, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the following upcoming investor conferences:2022 Jefferies Healthcare Conference on Wednesday, June 8th at 3:00 p.m. ET43rd Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 14th at 12:20 p.m. ETA live webcast of each presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation.About ModernaIn 10 ye

CAMBRIDGE, MA / ACCESSWIRE / May 18, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in a fireside chat at the UBS 2022 Global Healthcare Conference on Tuesday, May 24th at 9:15 a.m. ET.A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna's website for at least 30 days following the presentation.About ModernaIn over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field

CAMBRIDGE, MA / ACCESSWIRE / March 2, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the following upcoming investor conferences:Cowen 42nd Annual Health Care Conference on Wednesday, March 9th at 9:10 a.m. ETBarclays Global Healthcare Conference on Tuesday, March 15th at 1:30 p.m. ETOppenheimer 32nd Annual Healthcare Conference on Thursday, March 17th at 10:00 a.m. ETA live webcast of each presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna's web

CAMBRIDGE, MA / ACCESSWIRE/ January 4, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that CEO Stéphane Bancel will participate in a fireside chat at the Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference on Thursday, January 6th at 2:00 p.m. ET.A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna's website for 30 days following the presentation.About ModernaIn 10 years since its inception, Moderna has transformed from a science resea

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the following upcoming virtual investor conferences: NASDAQ 45th Investor Conference on Wednesday, December 1st at 9:30 a.m. ET Piper Sandler 33rd Annual Virtual Healthcare Conference on Wednesday, December 1st at 2:00 p.m. ET A live webcast of each presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation. About Moderna In 10 years since its ince

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the following upcoming virtual investor conferences: Bernstein Operational Decisions Conference on Thursday, November 4, 2021 at 4:30 p.m. ET Credit Suisse 30th Annual Healthcare Conference on Monday, November 8, 2021 at 1:50 p.m. ET A live webcast of each presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at https://investors.modernatx.com/. A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation. About Moderna In 10 year

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Stephen Hoge, M.D., President, will participate in a fireside chat at Chardan's Virtual 5th Annual Genetic Medicines Conference on Tuesday, October 5th at 1:00 p.m. ET. A live webcast of each presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna's website for 30 days following the presentation. About Moderna In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs i

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the following upcoming virtual investor conferences: Wells Fargo 2021 Virtual Healthcare Conference on Friday, September 10, 2021 at 10:00 a.m. ET Morgan Stanley 19th Annual Global Healthcare Conference on Friday, September 10, 2021 at 11:45 a.m. ET A live webcast of each presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of each webcast will be archived on Moderna's website for 30 days following the presentation. About Moderna In 10 years

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the following upcoming virtual investor conferences: Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 10:00 a.m. ET Goldman Sachs 42nd Annual Healthcare Conference on Wednesday, June 9, 2021 at 8:00 a.m. ET A live webcast of each presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at https://investors.modernatx.com/. A replay of each webcast will be archived on Moderna's website for 30 days following the presentation. About Moderna In 10 years since its ince

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that David Meline, Chief Financial Officer, and Lavina Talukdar, Senior Vice President & Head of Investor Relations, will participate in a fireside chat at the Bank of America 2021 Healthcare Conference on May 13th, 2021 at 11:00 a.m. ET. A live webcast will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna's website for 30 days following the presentation. About Moderna In 10 years since its inception, Moderna has transformed from a science

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that David Meline, Chief Financial Officer, and Lavina Talukdar, Senior Vice President & Head of Investor Relations, will participate in a fireside chat at the 20th Annual Needham Virtual Healthcare Conference on April 15th, 2021 at 11:45 a.m. ET. A live webcast will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna's website for 30 days following the presentation. About Moderna In 10 years since its inception, Moderna has transformed from

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the following upcoming virtual investor conferences: SVB Leerink 10th Annual Global Healthcare Conference on Thursday, February 25, 2021 at 1:00 p.m. ET. Cowen & Co. 41st Annual Health Care Conference on Monday, March 1, 2021 at 8:00 a.m. ET (panel presentation). Barclays Global Healthcare Conference on Thursday, March 11, 2021 at 10:20 a.m. ET. A live webcast of each presentation will be available under “Events and Presentations” in the Investors section of the Moderna website at investors.

CAMBRIDGE, Mass., Jan. 12, 2021 /PRNewswire/ -- Flagship Pioneering, a life science platforms company, today unveiled Pioneering Medicines, a new division of Flagship Pioneering. Initiated in 2020, Pioneering Medicines' mandate is to build a world-class biopharmaceutical R&D capability to conceive and develop a broad portfolio of life-changing treatments for patients.  By harnessing the power of Flagship's multiple scientific platforms, Pioneering Medicines will create and advance novel medicines that deliver benefits to more patients, sooner. Delivering Benefits to More Patients, Sooner Across the Flagship ecosystem, more than 40 companies are creating and applying innovative approaches

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Stéphane Bancel, Chief Executive Officer, will participate virtually in the Goldman Sachs 13th Annual Healthcare CEOs Unscripted Conference on January 5th, 2021 at 8:00 a.m. ET. A live webcast will be available under “Events and Presentations” in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna’s website for 90 days following the presentation. About Moderna Moderna is advancing messenger RNA (mRNA) science to create a new class of transf